Beneath the surface of allergic asthma, rhinitis, and eczema lies a shared distress signal: IL-33¹¹ IL-33
Interleukin-33, an alarmin cytokine stored in the nuclei of epithelial cells lining the airways, gut, and skin; released upon cell damage or allergen exposure, it binds the ST2 (IL1RL1) receptor on mast cells, ILC2 innate lymphoid cells, and eosinophils to initiate type-2 inflammation. rs1342326 sits approximately 25 kilobases upstream of the IL33 transcription start site on chromosome 9. The C allele acts as a gain-of-expression variant: carriers produce more IL-33 mRNA in bronchial epithelium, meaning every allergen challenge, viral rhinitis, or pollutant exposure generates a louder alarm. The GABRIEL consortium's genome-wide association study²² GABRIEL consortium's genome-wide association study
Moffatt et al. 2010, N=26,475; p=9×10⁻¹⁰ first established this SNP at genome-wide significance for asthma risk, and it has since been replicated across multiple European, Middle Eastern, and pediatric cohorts for asthma, allergic rhinitis, and hay fever.

The Mechanism

rs1342326 is a regulatory (eQTL) variant³³ regulatory (eQTL) variant
Expression quantitative trait locus — a variant that influences how much RNA is made from a nearby gene, without changing the protein sequence in the IL33 upstream regulatory region. The C allele is associated with measurably higher serum IL-33 protein concentrations in carriers, confirmed in the Tunisian pediatric cohort (Charrad et al. 2018)⁴⁴ (Charrad et al. 2018)
PMID 28985997. Higher constitutive IL-33 output means that the ST2/IL1RL1 receptor system — which mediates type-2 immune activation on mast cells, ILC2s, and eosinophils — is chronically primed above population baseline.

A second immune mechanism emerges from the PASTURE/EFRAIM birth cohort: C allele carriers show significantly reduced regulatory T cells (Tregs)⁵⁵ regulatory T cells (Tregs)
CD4+CD25+FOXP3+ cells that suppress immune overactivation; lower Treg frequency is associated with impaired allergen tolerance and higher atopic disease risk and elevated SOCS3 mRNA expression, which negatively correlates with Treg abundance (Schröder et al. 2016). This suggests that the rs1342326-C allele not only increases IL-33 output but also undermines the immune regulatory circuitry that normally limits Th2 responses — a compounding effect that helps explain the variant's association with multiple atopic phenotypes simultaneously.

The Evidence

The landmark GABRIEL GWAS⁶⁶ GABRIEL GWAS
Moffatt et al. NEJM 2010; 10,365 cases + 16,110 controls from European populations; genome-wide significance p=9×10⁻¹⁰ placed rs1342326 at the IL33 locus as one of the reproducible asthma risk signals, alongside IL1RL1 (ST2 receptor), HLA-DQ, and ORMDL3/GSDMB. The C allele risk allele frequency of ~16% in Europeans means a substantial fraction of the population carries at least one copy.

Pediatric longitudinal data strengthens the causal interpretation. In the Finnish post-bronchiolitis cohort⁷⁷ post-bronchiolitis cohort
Korppi et al. Acta Paediatr 2020; 141 children followed to ages 6 and 12, AC/CC carriers showed OR 2.17 for allergic rhinitis at age 6.4, rising to OR 3.23 at age 11.7 — a signal that strengthens over time, consistent with the progressive nature of atopic march. Notably, 22.5% of variant carriers required inhaled corticosteroids by age 6 versus only 8.9% of AA homozygotes.

In an Iranian adult case-control study (Matloubi et al. 2020⁸⁸ (Matloubi et al. 2020
126 asthmatics + 300 controls), the CC genotype carried OR 2.50 (95% CI 1.33–4.69) for asthma and was specifically associated with the atopic, eosinophil-elevated subtype. The elevated peripheral eosinophil counts in CC carriers confirm that the IL33-C eQTL effect flows through the IL-33→ST2→eosinophil axis, producing the quantitative biomarker signature consistent with type-2 high asthma.

An important pharmacogenomic signal comes from a Canadian pediatric exacerbation study⁹⁹ Canadian pediatric exacerbation study
Tse et al. Pediatr Pulmonol 2019; 491 children with acute moderate-to-severe asthma exacerbations: C allele carriers experienced significantly worse acute outcomes (management failure OR 0.52 for AA vs other genotypes), with higher rates of hospitalization and prolonged emergency care — suggesting that elevated IL-33 signaling during acute viral triggers drives more severe exacerbation phenotypes that are harder to control acutely.

Practical Implications

The C allele's mechanism — elevated IL-33 output → chronically primed ST2/eosinophil axis — points to two monitoring priorities: (1) tracking the downstream eosinophil and airway inflammation burden with FeNO and blood eosinophil count, and (2) being alert to the atopic march trajectory, particularly after early-life respiratory infections. IL-33 itself is now a pharmaceutical target: itepekimab (Dupixent's companion anti-IL-33 antibody) and tezepelumab (anti-TSLP, which synergises with IL-33 upstream) both mechanistically converge on the pathway amplified by this variant. Carriers with moderate-to-severe asthma are biologically well-matched to biologics that interrupt upstream type-2 signaling.

Interactions

rs1342326 (IL33 ligand, elevated expression) and rs1420101 (IL1RL1/ST2 receptor, reduced sST2 decoy expression) represent two nodes of the same IL-33 signaling axis. The rs1420101-T allele lowers circulating soluble ST2 — the natural IL-33 decoy receptor — so IL-33 is less buffered. Carrying C at rs1342326 and T at rs1420101 compounds both ends: more IL-33 released AND less decoy to intercept it. This interaction is documented in the literature on the IL-33/ST2 pathway and is captured in compound actions in this database. The related IL33 variant rs992969 tags a second upstream regulatory position also associated with increased IL33 expression; compound carriers of both IL33 risk alleles carry additive expression burden.

Clusterin (CLU), also known as apolipoprotein J, is the third strongest known genetic risk factor for late-onset Alzheimer's disease after APOE and BIN1. It is a secreted molecular chaperone that binds misfolded proteins — including amyloid-beta (Aβ) — and escorts them out of the brain across the blood-brain barrier. The rs1532278 variant sits in an intronic regulatory region of the CLU gene and is one of the most studied and most robustly replicated Alzheimer's risk loci in the entire human genome.

The Mechanism

CLU exerts its neuroprotective effect through two overlapping pathways. First, secreted clusterin forms stable complexes with Aβ and facilitates its clearance from the brain across the blood-brain barrier¹¹ blood-brain barrier
the highly selective barrier between brain tissue and circulating blood via the LRP2 receptor. Second, CLU inhibits Aβ oligomerization and aggregation directly, preventing the formation of the toxic soluble oligomers that damage synapses before plaques ever appear.

Rs1532278 is located in an intronic open chromatin region — a regulatory element — in glutamatergic (excitatory) neurons. A 2025 study using CRISPR editing of human iPSC-derived neurons showed that only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons²² only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons
Zhao et al., Molecular Neurodegeneration, 2025. The T allele creates stronger binding for the ISL2 transcription factor, retaining approximately 80% more binding capacity than the C allele. This drives elevated neuronal CLU transcription and secretion.

The protective T allele's downstream effect is measurable: T/T carriers show approximately 40–50% higher CLU mRNA expression in glutamatergic neurons compared to C/C carriers, along with greater dendritic complexity, enhanced synaptic marker expression, and higher neuronal firing frequency. Elevated neuronal CLU promotes neuron-to-astrocyte lipid transfer, increasing astrocytic lipid droplet accumulation and fine-tuning glutamate clearance — a lipid-mediated neuron-glia communication pathway that supports neuronal resilience.

The Evidence

CLU was first identified as an Alzheimer's risk locus in the landmark 2009 Harold et al. GWAS³³ 2009 Harold et al. GWAS
Harold et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009 (5,964 cases + controls, OR = 0.86 for the protective haplotype). Rs1532278 is in near-complete linkage disequilibrium with rs11136000 (r² = 0.95, D′ = 0.99), the originally reported CLU lead SNP — but rs1532278 shows slightly stronger association with ventricular expansion and Aβ deposition, suggesting it sits closer to the true causal variant.

A 2010 meta-analysis confirmed the CLU association across 15,000+ individuals⁴⁴ confirmed the CLU association across 15,000+ individuals
Jun et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci. Archives of Neurology, 2010 (OR = 0.91, 95% CI 0.85–0.96), and showed the CLU effect is independent of APOE ε4 status — unlike PICALM, whose effect is largely confined to ε4 carriers. The 2025 functional study reported an even more significant signal at rs1532278 specifically: OR = 0.905 with p = 3.2 × 10⁻³³ in a large meta-GWAS.

Plasma clusterin levels serve as a biomarker for AD progression. Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6⁵⁵ Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6
Jongbloed et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. J Alzheimers Dis, 2015 and correlated with faster cognitive decline (r = −0.38). Notably, C/C homozygotes have higher plasma clusterin concentrations, reflecting a compensatory upregulation in response to reduced brain clearance efficiency.

Practical Actions

Rs1532278 C/C and C/T carriers do not have a pathogenic variant — this is a common risk-modifying SNP, not a disease-causing mutation. The C allele is carried by approximately 86% of people in some form (C/C or C/T). Practical focus for C-allele carriers is on lifestyle factors that support the CLU-Aβ clearance pathway: omega-3 fatty acids support neuronal membrane integrity and reduce neuroinflammation at CLU-relevant pathway nodes; aerobic exercise increases CLU expression in hippocampal tissue; and avoiding chronic sleep deprivation is specifically relevant because Aβ clearance via the glymphatic system is maximally active during deep sleep — a pathway that overlaps functionally with CLU-mediated BBB clearance.

Monitoring cognition from midlife is meaningful for C/C homozygotes: baseline cognitive assessments with standardized tools (MoCA or MMSE) in the 40s–50s provide early-change detection before symptoms are clinically apparent.

Interactions

The strongest known interaction is with APOE. APOE ε4 and CLU risk alleles both impair Aβ clearance through related but distinct mechanisms — APOE via direct Aβ binding competition and receptor-mediated clearance at LRP1, CLU via LRP2 — and carriers of both risk alleles show amplified ventricular expansion rates and accelerated Aβ accumulation in imaging studies. This CLU × APOE interaction is documented in the literature and is a strong candidate for a compound action (see interaction candidates below).

The CLU locus also contains rs9331888 (exon 1) and rs7982 (exon 5), which affect alternative splicing of CLU transcripts in a sex-dependent manner. These three variants are in partial LD and tag different functional effects within the same gene — rs1532278 affects transcription in neurons, rs9331888 affects splicing, and rs7982 affects intron retention primarily in females.

Deep inside chromosome 9 lies a short stretch of DNA — the 9p21.3 locus — that carries some of the most replicated disease associations ever discovered. Within this region sits ANRIL (antisense non-coding RNA in the INK4 locus), a long non-coding RNA that acts as a molecular volume knob for cellular senescence. Variants in ANRIL are associated, in the same region of the genome, with coronary artery disease, myocardial infarction, type 2 diabetes, intracranial aneurysm, glioma, and physical aging — a concentration of GWAS hits rare in the human genome¹¹ a concentration of GWAS hits rare in the human genome
Pasmant E et al. ANRIL, a long noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011..

rs1537373 is an intronic variant within the ANRIL gene itself (CDKN2B-AS1), positioned at chromosome 9, base 22,103,342 on the GRCh38 reference. It is one of several independent tag SNPs at this locus, each capturing a partially distinct signal. The T allele at rs1537373 is the risk allele for myocardial infarction and brain aneurysm, while the locus as a whole — through nearby variants in strong linkage disequilibrium — also confers type 2 diabetes susceptibility.

The Mechanism

ANRIL is transcribed antisense to three protein-coding genes packed tightly together at 9p21.3: CDKN2B (encoding p15INK4b), CDKN2A (encoding p16INK4a and p14ARF), and MTAP. p15 and p16 are cyclin-dependent kinase inhibitors²² cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4 and CDK6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint that drive cellular senescence. As cells accumulate damage or age, rising p16 and p15 levels lock them in a permanent growth arrest — senescent "zombie" cells³³ senescent "zombie" cells
Senescent cells remain metabolically active but stop dividing, secreting pro-inflammatory cytokines (the SASP) that progressively damage surrounding tissue that fuel atherosclerosis and impair tissue regeneration.

ANRIL regulates CDKN2A/CDKN2B expression in cis by recruiting PRC2 (Polycomb Repressive Complex 2)⁴⁴ PRC2 (Polycomb Repressive Complex 2)
PRC2 deposits repressive H3K27me3 histone marks that silence nearby genes; loss of PRC2 recruitment allows CDKN2A/2B to be more highly expressed, accelerating senescence to silence the INK4 locus. Variants at rs1537373 alter the expression of specific ANRIL isoforms, shifting the balance toward either more or less CDKN2A/2B expression in vascular and pancreatic tissues. In vascular smooth muscle cells (VSMCs), elevated p16/p15 accelerates VSMC senescence and plaque-forming behavior, driving atherosclerosis. In pancreatic beta cells, the same pathway reduces proliferative capacity and total beta-cell mass over decades, impairing insulin production.

Notably, the cardiovascular and T2D-associated SNPs within the 9p21 locus are largely non-overlapping⁵⁵ the cardiovascular and T2D-associated SNPs within the 9p21 locus are largely non-overlapping
Kong et al. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease. Front Endocrinol. 2018. PMID:30087655, suggesting distinct ANRIL isoforms and regulatory elements govern each disease phenotype — with rs1537373 primarily tagging the cardiovascular signal at this multi-trait locus.

The Evidence

The 9p21 locus entered the cardiovascular genetics literature with force in 2007. Helgadottir et al.⁶⁶ Helgadottir et al.
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007. PMID:17478679 showed that approximately 21% of the population is homozygous for the risk variant at 9p21, and their estimated MI risk is 1.64 times that of noncarriers — rising to 2.02-fold for early-onset MI. The population attributable risk from this single locus was estimated at 21% for general MI and 31% for early-onset disease.

At the same time, Samani et al. 2007⁷⁷ Samani et al. 2007
Genomewide association analysis of coronary artery disease. NEJM 2007. PMID:17634449 confirmed the 9p21 region (lead SNP rs1333049, in strong LD with rs1537373) as the single strongest genetic risk locus for coronary artery disease ever identified, with a per-allele OR of 1.36 (95% CI 1.27–1.46). These findings have been replicated consistently across dozens of independent cohorts.

GWAS Catalog data specific to rs1537373 shows genome-wide significant associations with myocardial infarction (p = 2×10⁻⁷¹), brain aneurysm (p = 3×10⁻²² to 3×10⁻²⁹), coronary artery calcification (p = 4×10⁻¹¹), heart failure (p = 2×10⁻¹²), and LDL cholesterol elevation (p = 5×10⁻¹⁷).

The T2D connection at this locus was established by three concurrent 2007 GWAS that identified nearby 9p21 variants (rs10811661, rs564398) as independent T2D susceptibility signals. A meta-analysis by Cugino et al.⁸⁸ meta-analysis by Cugino et al.
Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc Dis 2012. PMID:21315566 across 22 studies (38,455 T2D cases, 60,516 controls) confirmed per-allele OR 1.24 (P < 10⁻¹⁵) for the primary 9p21 T2D signal, with 15% population attributable risk in Caucasians.

Practical Actions

The GWAS catalog T-allele associations for rs1537373 cover both acute cardiovascular events (MI, aneurysm) and metabolic disease (T2D, LDL). Actions at this locus target:

• Reducing atherosclerotic plaque progression through dietary and monitoring strategies
• Catching asymptomatic coronary artery disease early, when intervention is most effective
• Managing the metabolic stressors that exhaust beta-cell reserves

A critical finding: Do et al. 2012⁹⁹ Do et al. 2012
INTERHEART and FINRISK study of diet-gene interaction at 9p21. PMID:22022235 showed that among those with the highest "prudent diet" scores (rich in raw vegetables and fruits), the 9p21 genetic risk for MI was effectively abolished. Among those with low prudent diet scores and two risk alleles, MI risk was doubled. The dietary interaction at this locus is one of the strongest gene-diet interactions in cardiovascular genetics.

Interactions

rs1537373 is in strong linkage disequilibrium with the primary CAD variant rs1333049 and with the T2D variants rs10811661 and rs564398 — all within the same ~200 kb stretch of 9p21.3. These variants together capture overlapping but distinct regulatory signals within the ANRIL locus. Carrying risk alleles at multiple 9p21 positions compounds risk across cardiovascular and metabolic phenotypes through shared cellular senescence biology.

The longevity-associated rs2811712 within ANRIL (covered in the Longevity & Aging category) represents a further independent signal at the same gene, primarily associated with age-related physical function and frailty — illustrating how different ANRIL isoforms modulate distinct tissue-specific aspects of aging.

Methionine synthase reductase (MTRR) maintains the one-carbon methylation cycle by reactivating methionine synthase (MTR) after its methylcobalamin cofactor becomes oxidized during catalysis. When MTRR function is impaired — whether by coding variants that reduce enzyme efficiency or by regulatory variants that reduce enzyme expression — homocysteine accumulates and global DNA methylation declines, processes linked to genomic instability and tumor suppressor silencing.

rs162040 is an intronic variant at chromosome 5 position 7,887,365 (GRCh38), within an MTRR haplotype block also containing rs3776467, rs326124, and rs3776455. The GRCh38 reference allele at this position is C, but C is the population minority (~11% globally in gnomAD v4, ~31% in East Asian populations). The common A allele (~89% globally) represents the baseline protective state; the C allele marks the risk haplotype.

The Mechanism

As an intronic variant, rs162040 does not alter the MTRR protein sequence. Its biological significance lies in its membership in a functional MTRR regulatory haplotype. The parallel between rs162040 and the neighboring intronic variants rs3776467 and rs326124 — all showing the same alcohol-modulated survival signal in the same dataset — suggests they tag a shared regulatory element or splice-regulatory sequence within MTRR introns. Such elements can influence MTRR transcript levels or alternative splicing¹¹ MTRR transcript levels or alternative splicing
Intronic regulatory elements including branch point sequences, exonic splicing enhancers, and lncRNA binding sites can alter gene expression without changing the protein coding sequence. Reduced MTRR expression would impair B12 reactivation, slowing MTR-catalyzed homocysteine remethylation and depleting SAM (the universal methyl donor) — the same downstream consequence as coding impairments.

The Evidence

The primary evidence comes from the Newfoundland Familial Colorectal Cancer Study²² Newfoundland Familial Colorectal Cancer Study
Wang Y et al. The Roles of MTRR and MTHFR Gene Polymorphisms in Colorectal Cancer Survival. Nutrients, 2022, which followed 532 patients with newly diagnosed colorectal cancer (1999–2003) through April 2010. The study genotyped 33 MTRR and MTHFR tag SNPs and assessed their association with overall survival (OS) and disease-free survival (DFS).

For rs162040, as part of the MTRR haplotype block, a significant interaction was found with pre-diagnostic alcohol consumption: protective A-allele carriers showed superior overall survival, but this benefit was restricted to patients consuming alcohol below the cohort median of 2.17 g/day (roughly one standard drink per week). Among patients with higher alcohol intake, the allele-associated survival difference was abolished. This interaction pattern — replicated across rs162040, rs3776467, rs326124, and rs3776455 in the same analysis — is consistent with alcohol's known disruption of folate absorption and one-carbon methyl-donor homeostasis. Alcohol depletes intestinal folate uptake and increases urinary folate excretion, amplifying any underlying impairment of MTRR-dependent B12 recycling.

The evidence base is limited: one survival cohort study in CRC patients, with rs162040 analyzed as part of a haplotype block rather than as an isolated variant. No population-based homocysteine data, no in vitro MTRR expression studies, and no prospective healthy-population data exist for rs162040 specifically. Evidence level is emerging.

Practical Actions

For C-allele carriers, two modifiable factors interact with the rs162040 haplotype: alcohol intake and B12/folate status. Keeping alcohol intake consistently low removes the primary amplifying factor for MTRR-related methylation disruption. Using active B12 forms (methylcobalamin or hydroxocobalamin rather than cyanocobalamin) and methylfolate instead of synthetic folic acid supports the one-carbon cycle even when MTRR regulatory capacity is reduced.

Monitoring plasma homocysteine provides an objective readout of functional methylation status. Elevated homocysteine (above 10 µmol/L) with normal dietary B12 intake signals that recycling pathway demand exceeds capacity and warrants targeted supplementation.

Interactions

rs162040 sits in the same MTRR intronic haplotype block as rs3776467, rs326124, and rs3776455, all of which showed parallel alcohol-survival interactions in the Wang 2022 cohort. The coding variant rs1801394 (MTRR A66G, p.Ile22Met), which reduces MTRR catalytic efficiency, operates through a complementary mechanism — carriers of both the regulatory risk haplotype (rs162040 C allele) and the coding impairment (rs1801394 G allele) may face compounded MTRR dysfunction. Upstream impairments in MTHFR (rs1801133 C677T, reduced methylfolate production) or MTR (rs1805087 A2756G, reduced methionine synthase activity) further amplify the downstream consequences of impaired MTRR B12 recycling.

Brown adipose tissue (BAT) is the body's built-in furnace. Unlike white fat, which stores energy, brown fat burns calories by uncoupling the mitochondrial electron transport chain from ATP synthesis — dissipating energy directly as heat. The master switch for this process is uncoupling protein 1 (UCP1), encoded by the UCP1 gene on chromosome 4q31. The A-3826G polymorphism (rs1800592) sits in the promoter region, approximately 3,826 base pairs upstream of the UCP1 transcription start site, where it directly influences how much UCP1 the body can produce.

The Mechanism

UCP1 is on the minus (reverse) strand of chromosome 4. In the standard literature notation, the variant is described as A→G at position -3826; on the plus strand that 23andMe reports, the protective "A" allele appears as T and the risk "G" allele appears as C. This regulatory SNP¹¹ regulatory SNP
A single-nucleotide change in non-coding DNA that alters gene expression rather than protein structure lies within a complex enhancer region (positions -3820 to -3470) containing multiple cis-acting elements, including a putative retinoic acid response element and an ATF/CREB-like binding site. Transfection experiments demonstrate that the haplotype containing the protective A allele (T on plus strand) drives significantly higher luciferase reporter activity than the G-risk haplotype (C on plus strand), with the GG haplotype showing virtually no basal transcriptional activity. In obese individuals, G-allele carriers have measurably reduced UCP1 mRNA expression²² reduced UCP1 mRNA expression
Confirmed in adipose tissue biopsies; the G allele impairs promoter activity and downstream thermogenic signaling, translating the promoter SNP directly into reduced thermogenic protein abundance.

The Evidence

The functional consequences appear across multiple physiological contexts. In the earliest human study, Ridderstrale et al. (2003)³³ Ridderstrale et al. (2003)
88 healthy boys aged 8-11; indirect calorimetry after high-fat and high-carbohydrate test meals; JCEM 88(12):5661 showed that after a high-fat meal, GG boys had a significantly lower thermic effect of the meal than AA+AG boys, despite identical sympathetic nervous system activation — the signal to burn calories via UCP1 was present but the thermogenic machinery was impaired.

At rest, the deficit is also measurable. Nagai et al. (2011)⁴⁴ Nagai et al. (2011)
82 healthy young females aged 20-22; indirect calorimetry; International Journal of Obesity 35:1038 found resting energy expenditure was 14% higher in AA women than GG women (5,599 vs 4,919 kJ/day, p<0.01), with AG women intermediate (5,054 kJ/day). Thermoregulatory sympathetic nervous system activity (measured by heart rate variability spectral analysis) was similarly lowest in GG subjects.

Cold exposure reveals the deficit most starkly. Kooijman et al. (2014)⁵⁵ Kooijman et al. (2014)
19 healthy children; acute cold exposure; Pediatric Research 75:227 showed GG children produced less heat when cold-challenged, despite mounting a stronger hormonal stress response (elevated cortisol and autonomic activation) — a costly compensatory effort that failed to fully bridge the thermogenic gap. A 2017 mechanistic study in 47 Japanese males confirmed that AA homozygotes show significantly greater oxygen consumption during cold exposure⁶⁶ AA homozygotes show significantly greater oxygen consumption during cold exposure
VO2 increase p=2.4×10⁻³ to 8.1×10⁻³ across comparison timepoints than heterozygotes or CC carriers.

Long-term consequences emerge through two pathways. First, BAT naturally declines with age, and Yoneshiro et al. (2012)⁷⁷ Yoneshiro et al. (2012)
199 volunteers aged 20-72; FDG-PET/CT after cold exposure; International Journal of Obesity 37:96 found that the G allele (plus-strand C) significantly accelerates this decline: in older subjects, GG individuals had 0% BAT detection rate vs 24% in A-allele carriers (p<0.05), with correspondingly higher visceral fat. Second, brown fat's impact is strongly seasonal: Yoneshiro et al. (2013)⁸⁸ Yoneshiro et al. (2013)
3,013 Japanese adults; seasonal sampling across entire year; PLOS ONE 8:e74720 showed UCP1 genotype predicted visceral fat area specifically during winter months (when BAT is most active), with effects tightly correlated with ambient outdoor temperature (p=0.00011). A Saudi case-control study Al-Daghri et al. (2018)⁹⁹ Al-Daghri et al. (2018)
337 obese vs 155 controls; adjusted OR; BMC Medical Genetics reported OR 1.52 (95% CI 1.10-2.08, p=0.009) for obesity in G-allele carriers. Meta-analyses examining BMI as a continuous outcome have been mixed, likely because the effect is strongest under cold stress rather than in thermoneutral laboratory conditions.

Practical Implications

For CC carriers (GG in traditional notation), the thermogenic gap is present under all conditions — at rest, after high-fat meals, and during cold exposure — but is most physiologically significant in cold environments and as age reduces BAT reserve. Interventions that activate brown fat through alternative pathways can partly compensate. Cold exposure directly stimulates BAT; even mild cool environments (17-19°C) trigger adrenergic BAT activation independent of UCP1 promoter activity. Capsinoids (non-pungent capsaicin analogs found in sweet peppers) activate BAT via the TRPV1 receptor–sympathetic nervous system axis, increasing resting energy expenditure in individuals with active BAT. High-fat meals elicit less diet-induced thermogenesis in GG carriers, making meal composition relevant; carbohydrate-containing meals appear to trigger more UCP1-independent thermogenic pathways.

Interactions

The most documented interaction is with ADRB3 rs4994 (Trp64Arg, β3-adrenergic receptor), which modulates catecholamine-driven BAT activation. Yoneshiro et al. (2012)¹⁰¹⁰ Yoneshiro et al. (2012) showed that the combination of UCP1 G allele and ADRB3 Trp64Arg significantly accelerates age-related BAT decline more than either allele alone. In older adults carrying both risk variants, BAT detection rates were effectively zero and visceral fat accumulation was highest. A Brazilian study found the combined presence of three or more risk alleles across ADRB3 Trp64Arg and UCP1 -3826A/G correlated with protection against overweight when the protective alleles were present (OR=0.288 for overweight with at least three minor alleles). If you also carry the ADRB3 Trp64Arg variant (rs4994), the combined impairment in adrenergic BAT stimulation and UCP1 expression warrants more aggressive cold-exposure and lifestyle strategies than for UCP1 alone.

CYP2C8 is one of the liver's key drug-metabolizing enzymes, responsible for breaking down a broad range of therapeutics including paclitaxel (a widely used chemotherapy agent), thiazolidinedione diabetes drugs, and antimalarials. Beyond drug metabolism, CYP2C8 converts arachidonic acid into epoxyeicosatrienoic acids ¹¹ EETs: lipid mediators with vasodilatory and anti-inflammatory properties, meaning it plays a role in vascular regulation and inflammation even in people who never take any of its substrate drugs.

rs1934951 is an intronic variant²² Intronic: located within a non-coding region between two exons of the CYP2C8 gene in CYP2C8 that has attracted attention primarily in two clinical contexts: bisphosphonate-related osteonecrosis of the jaw (MRONJ) in cancer patients, and taxane-induced peripheral toxicity in chemotherapy recipients.

The Mechanism

The rs1934951 T allele (reported as the A allele in papers using the coding strand, since CYP2C8 is on the minus strand of chromosome 10) falls within intron 9 of CYP2C8 at position c.1291+106. As an intronic variant with no direct protein-coding effect, its functional mechanism is not fully established. It may act as a tag for CYP2C8 haplotype C (HapC), which is associated with altered enzyme activity and expression. CYP2C8 haplotypes differ in their efficiency of substrate metabolism; carriers of HapC may have modified clearance of paclitaxel and potentially altered EET production from arachidonic acid. Bisphosphonates are not CYP2C8 substrates per se, but CYP2C8-driven EET signaling influences osteoclast³³ Osteoclasts: bone-resorbing cells regulated in part by EET lipid mediators activity and bone microvasculature, providing a plausible biological link.

The Evidence

The original finding came from a genome-wide association study in multiple myeloma patients⁴⁴ genome-wide association study in multiple myeloma patients
Sarasquete ME et al. Bisphosphonate-related osteonecrosis of the jaw associated with CYP2C8 polymorphisms. Blood, 2008 receiving bisphosphonates. In 22 cases of jaw osteonecrosis versus 65 matched controls, the T allele (papers call it A) was dramatically overrepresented in cases (48% vs 12%), with homozygous TT carriers at 12.75-fold increased risk (OR 12.75, 95% CI 3.7–43.5, p-corrected = 0.02). A meta-analysis by Zhong et al. (2013)⁵⁵ Zhong et al. (2013)
Zhong DN et al. CYP2C8 rs1934951 polymorphism meta-analysis. Acta Haematol, 2013 found the association held specifically in multiple myeloma patients (dominant model OR 5.77, p=0.028) but not across other cancer types.

However, a comprehensive review by Yang et al. (2019)⁶⁶ Yang et al. (2019)
Yang G et al. Pharmacogenomics of osteonecrosis of the jaw. Bone, 2019 concluded that all six subsequent candidate-gene replication studies failed to confirm this association, attributing the original signal to the small sample size of the discovery GWAS. The MRONJ association must therefore be treated as an initial discovery finding that has not been independently validated.

The chemotherapy toxicity evidence is more consistent. A study of 113 breast cancer patients found rs1934951 significantly associated with paclitaxel-induced anemia (p≤0.01), in conjunction with CYP2C8 haplotype C Boso et al. 2014⁷⁷ Boso et al. 2014
Bosó V et al. SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics, 2014. A more recent multicenter cohort study of 130 ovarian cancer survivors (median 63-month follow-up after chemotherapy) found that T-allele carriers had approximately 2.5-fold increased odds of experiencing severe long-term chemotherapy-induced peripheral neuropathy (OR 2.482, 95% CI 1.13–5.47, p=0.024) Zenatri et al. 2024⁸⁸ Zenatri et al. 2024
Zenatri M et al. Pharmacogenomic predictor of long-term residual CIPN in ovarian cancer survivors. Gynecol Oncol, 2024.

Practical Actions

For individuals who may receive or are considering paclitaxel-based chemotherapy (used in breast, ovarian, lung, and other cancers), T-allele carriers — especially TT homozygotes — should discuss their genotype with their oncologist. Preventive neuropathy management strategies (such as dose modification, cold-cap gloves during infusion, and early physical therapy) are most effective when implemented proactively. For those receiving bisphosphonates (zoledronic acid, pamidronate) for bone protection or myeloma treatment, the MRONJ association remains biologically plausible but replication data is inconsistent; basic dental hygiene protocols before starting bisphosphonate therapy are standard of care for all patients regardless of genotype.

Interactions

rs1934951 may act as a tag for the CYP2C8 haplotype C (HapC), which is defined by a combination of variants including rs10509681 and rs11572080 — other intronic CYP2C8 SNPs also studied in the context of taxane-induced neuropathy. In pharmacogenomics studies, the haplotype may confer stronger predictive value than any single variant alone. The interaction between CYP2C8 metabolizer status and paclitaxel dose intensity has not yet been formalized into CPIC or DPWG guidelines, but multiple independent signals in the same gene strengthen the biological rationale.

The FADS2 gene encodes delta-6 desaturase¹¹ delta-6 desaturase
delta-6 desaturase (D6D) is the rate-limiting enzyme in the conversion of linoleic acid (LA) and alpha-linolenic acid (ALA) to their longer-chain products, the gateway enzyme controlling how your body converts essential fatty acids from food into the biologically active long-chain polyunsaturated fatty acids (LC-PUFAs) — including arachidonic acid (AA), EPA, and DHA. rs2072114 is an intronic SNP in the first intron of FADS2, sitting within the broader FADS1/FADS2 haplotype block²² FADS1/FADS2 haplotype block
A haplotype block is a stretch of DNA where nearby variants tend to be inherited together as a unit on chromosome 11q12-13. Though non-coding, it serves as a reliable tag for functional variation in this cluster that modulates desaturase enzyme output.

The Mechanism

Delta-6 desaturase performs the first and most critical step in converting short-chain dietary omega-6 and omega-3 fatty acids into their longer, more bioactive derivatives. For omega-6s: LA → GLA → DGLA → AA. For omega-3s: ALA → SDA → EPA → DHA. The G allele of rs2072114 is associated with altered n-6 desaturase activity — the direction of effect (increased or decreased) is population- and sex-specific, reflecting interactions between genetic background and hormonal environment. In populations studied, the net result tends to shift fatty acid profiles toward lower arachidonic acid production relative to linoleic acid precursor, and may reduce delta-5 and delta-6 desaturase efficiency for certain conversions in specific subgroups.

Because rs2072114 lies within a strong linkage disequilibrium block, its observed associations partly reflect correlated effects of neighboring functional FADS2 variants (rs174575, rs174576, rs174602) rather than a direct effect of the intronic position itself.

The Evidence

A cross-sectional study by Abdelmagid et al.³³ cross-sectional study by Abdelmagid et al.
Abdelmagid et al. Ethnicity, sex, FADS genetic variation, and hormonal contraceptive use influence delta-5- and delta-6-desaturase indices and plasma DHA concentration in young Canadian adults. Nutr Metab, 2015 of 787 Caucasian and East Asian young adults found that rs2072114 was significantly associated with aggregate n-6 desaturase indices, with effects that were ethnicity- and sex-specific. East Asian females showed the most pronounced associations after multiple-testing correction.

A Taiwanese clinical study by Huang et al.⁴⁴ Taiwanese clinical study by Huang et al.
Huang et al. Interaction among dietary n-3 and n-6 PUFA intake, FADS2 genetic variants, and LDL-C in type 2 diabetes patients. J Diabetes Investig, 2023 in 816 type 2 diabetes patients found that the G allele of rs2072114 showed a significant gene-diet interaction (P = 0.016): among individuals with a low alpha-linolenic acid/linoleic acid ratio in their diet, G allele carriers had lower LDL-C concentrations. This suggests the metabolic effect of this variant is diet-sensitive and most pronounced when omega-3 dietary intake is relatively low.

Broader evidence for the FADS1/FADS2 locus⁵⁵ FADS1/FADS2 locus
Tanaka et al. GWAS of plasma PUFA in InCHIANTI study. PLoS Genet, 2009 confirms this genomic region is the dominant genetic determinant of circulating PUFA levels — the lead SNP rs174537 explains 18.6% of variance in arachidonic acid concentrations. rs2072114 tags this same haplotype block.

Practical Actions

The G allele's effect on fatty acid desaturation is context-dependent. The most robust intervention is ensuring a dietary n-3/n-6 ratio that limits the functional impact of reduced conversion efficiency. G allele carriers benefit from increasing preformed EPA and DHA from marine or algae-based sources, rather than relying solely on ALA conversion from plant oils. Monitoring lipid panels — particularly LDL-C in the context of dietary fatty acid composition — gives personalized feedback on whether the genetic effect is clinically active.

Interactions

rs2072114 sits within the same haplotype block as rs174547 (FADS1) and rs174575, rs174576, rs174602 (FADS2). Carriers of multiple variant alleles across this cluster may have additive reductions in both delta-5 and delta-6 desaturase activity, amplifying the need for preformed LC-PUFAs. The ELOVL2 gene (rs953413, chromosome 6) is a pathway partner — it handles the elongation step after FADS2 has performed initial desaturation, so combined variation across FADS2 and ELOVL2 can further reduce DHA synthesis efficiency.

mTOR (mechanistic target of rapamycin) is arguably the most powerful longevity-relevant kinase in human biology. It integrates signals from nutrients, amino acids, growth factors, and energy status to control cell growth, protein synthesis, and — critically — autophagy¹¹ autophagy
the cellular garbage-disposal process that clears damaged proteins and organelles; inhibition of mTOR is the primary trigger for autophagy induction. When mTOR activity is chronically high, cells prioritize growth and suppress the housekeeping functions that prevent aging; when mTOR is appropriately restrained, autophagy runs, senescent cells are cleared, and lifespan extends across every organism where this has been tested.

The rs2295080 T>G variant sits in the promoter of the MTOR gene on chromosome 1 and acts as a functional dimmer switch for mTOR expression. Individuals carrying the G allele have measurably lower MTOR mRNA levels in their tissues, confirmed by luciferase reporter assays showing the G allele significantly decreases promoter transcriptional activity. The G allele essentially dials mTOR expression down²² The G allele essentially dials mTOR expression down
Cao Q et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLOS One, 2012.

The Mechanism

rs2295080 is located approximately 2 kb upstream of the MTOR coding sequence, placing it in the core promoter region that controls transcription initiation. The T→G change alters a transcription factor binding site, reducing the efficiency with which the transcriptional machinery assembles and initiates MTOR mRNA production. The result is a genotype-dependent gradient of mTOR activity: TT > GT > GG.

Lower constitutive mTOR expression has several downstream effects. mTORC1 (the nutrient-sensing complex) phosphorylates S6 kinase and 4E-BP1 to drive protein synthesis; when this activity is reduced, cells shift resources toward protein quality control and autophagy induction. mTOR inhibition also extends lifespan in yeast, worms, flies, and mice — rapamycin, which blocks mTORC1, is the only pharmacological agent that robustly extends lifespan in all model organisms tested³³ mTOR inhibition also extends lifespan in yeast, worms, flies, and mice — rapamycin, which blocks mTORC1, is the only pharmacological agent that robustly extends lifespan in all model organisms tested
Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging, 2023. Genetic lower expression via rs2295080 may mimic, in a modest and constitutive way, the longevity biology of intermittent mTOR suppression.

The Evidence

The primary evidence base for rs2295080 consists of cancer risk studies, which are the clearest functional readout of mTOR overactivity: elevated mTOR drives cell proliferation and suppresses apoptosis, so genotypes with higher mTOR expression should show elevated cancer susceptibility.

Gastric cancer (n=1,607)⁴⁴ Gastric cancer (n=1,607)
Xu M et al. A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLOS One, 2013: the G allele was associated with a 23% lower risk of gastric cancer (OR 0.77, 95% CI 0.65–0.92, P=0.004).

Colorectal cancer (n=1,514)⁵⁵ Colorectal cancer (n=1,514)
Xu M et al. Functional promoter rs2295080 T>G variant in MTOR gene is associated with risk of colorectal cancer in a Chinese population. Biomed Pharmacother, 2015: carriers of TG or GG genotypes had a 24% lower risk of colorectal cancer (OR 0.76, 95% CI 0.62–0.94, P=0.011); the effect was stronger in men and the elderly (OR 0.63 and 0.66, respectively).

Renal cell cancer (n=1,470)⁶⁶ Renal cell cancer (n=1,470)
Cao Q et al. 2012: the G allele was associated with reduced RCC risk (OR 0.74, 95% CI 0.59–0.91, P=0.005).

Breast cancer (n=1,143)⁷⁷ Breast cancer (n=1,143)
Zhao Y et al. 2016: GG homozygotes had a 55% lower breast cancer risk (OR 0.45, 95% CI 0.23–0.91, P=0.02) and lower rates of lymph node metastasis.

A comprehensive meta-analysis of 18 Chinese studies⁸⁸ A comprehensive meta-analysis of 18 Chinese studies
Qi GH et al. 2020 confirmed decreased risk for urinary system tumors and prostate cancer (heterozygote OR 0.80, P<0.001), while noting a paradoxical increased leukemia risk in GG homozygotes — a finding that requires further study and likely reflects cancer-type-specific mTOR biology.

Most studies have been conducted in Chinese populations; replication in European and other populations is warranted, which is reflected in the moderate evidence rating.

Practical Actions

The actionable implications of rs2295080 center on how your genotype shapes the ideal strategy for managing mTOR activity over time. Regardless of genotype, mTOR is suppressed by fasting, protein restriction, and exercise, and activated by dietary protein (especially leucine/BCAAs), insulin, and growth factors. But the baseline level of MTOR expression differs by genotype, which affects how aggressively these lifestyle tools need to be applied.

TT carriers have higher constitutive mTOR activity — they benefit most from deliberate mTOR-suppression protocols: extended overnight fasting (14–16 hours), periodic protein cycling (low protein days), and close attention to protein timing relative to meals. GT carriers have an intermediate baseline and similar considerations at lower urgency. GG carriers enjoy naturally lower mTOR expression, meaning their cells engage autophagy more readily, but they may also need to ensure adequate protein intake to support muscle protein synthesis since mTOR plays a key anabolic role.

Interactions

rs2295080 is part of the broader PI3K-AKT-mTOR signaling axis. Related SNPs worth considering include rs2536 (another mTOR variant studied for cancer risk), and upstream regulators like variants in PTEN (which normally suppresses AKT/mTOR activity) and AMPK pathway genes. FOXO3A (rs2802292) operates in the same longevity signaling network: FOXO3 is normally phosphorylated and inactivated by AKT downstream of mTOR, so G-allele carriers at both rs2295080 (lower mTOR) and rs2802292 (higher stress-induced FOXO3 expression) would be expected to have complementary longevity biology through this pathway. This interaction is biologically plausible but has not been formally tested in a combined genotype study.

Estrogen receptor alpha (ERα), encoded by the ESR1 gene on chromosome 6q25.1, is one of the body's most important hormone receptors. It mediates estrogen's protective effects across multiple systems — from promoting vasodilation and suppressing vascular inflammation in the cardiovascular system, to regulating cell proliferation and differentiation in breast tissue. The rs2881766 polymorphism sits within an intron of ESR1 and has been associated with two distinct but mechanistically connected phenotypes: risk of pregnancy-induced hypertension (PIH/gestational hypertension) and breast cancer susceptibility. Both reflect the broader consequence of altered estrogen receptor signaling across different physiological contexts.

The Mechanism

rs2881766 is located at chr6:151,797,984 on the GRCh38 plus strand, within an intron of the ESR1 gene. As an intronic variant, it does not change the ERα protein sequence directly. Instead, intronic variants in ESR1 are thought to act through regulatory mechanisms — altering [splicing efficiency | intronic variants can affect how exons are joined together during mRNA processing], modifying transcription factor binding within intron-derived regulatory elements, or serving as [tag SNPs | a tag SNP is in linkage disequilibrium with a nearby functional variant and marks that variant in association studies] for nearby functional variants that have not yet been individually characterized.

The T allele (GRCh38 reference) appears to be the risk-associated allele. In the context of pregnancy-induced hypertension, estrogen's role in vascular adaptation is essential: during normal pregnancy, rising estrogen levels promote nitric oxide synthesis, endothelial relaxation, and the dramatic increase in uterine blood flow required to sustain fetal growth. Impaired ESR1 signaling — whether through reduced expression or altered receptor function — could blunt these vascular adaptations, contributing to hypertensive complications.

In breast tissue, ERα is the primary driver of estrogen-stimulated cell proliferation. Variants that alter ESR1 expression levels or receptor activity can shift the balance between proliferative and protective estrogen signaling, influencing breast cancer susceptibility.

The Evidence

The cardiovascular association was established in a haplotype-based case-control study of 95 Japanese women with PIH and 200 matched controls¹¹ haplotype-based case-control study of 95 Japanese women with PIH and 200 matched controls
Tamura M et al. Hypertens Res 2008;31(2):221-8. The T allele of rs2881766 was significantly more prevalent in the PIH group. Haplotype analysis revealed that the G-A combination at rs2881766-rs1643821 and the G-A-T combination at rs2881766-rs1643821-rs988328 were protective against PIH — confirming that the G allele tags the protective haplotype and the T allele marks the susceptibility configuration. This finding is biologically coherent with estrogen's known role in maintaining gestational vascular homeostasis.

The breast cancer associations have been documented across multiple Asian populations. In a Chinese Han cohort of 459 cases and 549 controls, the GG genotype was associated with decreased breast cancer risk (OR=0.63, 95% CI 0.44–0.91) compared to TT²² the GG genotype was associated with decreased breast cancer risk (OR=0.63, 95% CI 0.44–0.91) compared to TT
Dai Z et al. Cancer Cell Int 2019;19:9. The GG genotype also correlated with lymph node metastasis status and estrogen receptor expression in tumors, suggesting rs2881766 influences the estrogen-driven biology of breast cancer.

A larger Korean study of 830 breast cancer cases and 390 controls found that rs2881766 increased breast cancer risk across all three age groups examined — premenopausal women under 35, premenopausal women over 35, and postmenopausal women — and across multiple tumor subtypes³³ rs2881766 increased breast cancer risk across all three age groups examined — premenopausal women under 35, premenopausal women over 35, and postmenopausal women — and across multiple tumor subtypes
Son BH et al. J Cancer Res Clin Oncol 2015;141(4):633-45. A smaller Han Chinese study of 198 cases and 218 controls additionally found that the GG genotype elevated risk in women with later menarche (>13 years), suggesting the variant's effect may interact with cumulative estrogen exposure⁴⁴ suggesting the variant's effect may interact with cumulative estrogen exposure
Chen L et al. Gynecol Endocrinol 2016;32(7):553-6.

Evidence is currently at the moderate level — associations are replicated in multiple independent Asian cohorts, with a plausible biological mechanism, but large European or multi-ancestry meta-analyses specifically examining rs2881766 are lacking.

Practical Implications

The strongest actionable signal from rs2881766 is in the context of pregnancy. Women with the TT genotype who are pregnant or planning pregnancy face a modestly elevated risk of gestational hypertension and should ensure their blood pressure is monitored throughout pregnancy, particularly in the second and third trimesters. The cardiovascular protective role of estrogen signaling is most critical during pregnancy and in the years around menopause, when estrogen levels shift dramatically.

The breast cancer association identifies TT carriers as having relatively higher estrogen-driven breast cancer risk. This makes awareness of estrogen-amplifying exposures — including combined oral contraceptives and menopausal hormone therapy — particularly relevant for risk-benefit discussions with a healthcare provider.

Interactions

rs2881766 exists within a haplotype context with other ESR1 variants. The PIH study demonstrated that the protective effect is carried by the G-A haplotype across rs2881766 and rs1643821, meaning the combination of alleles matters more than rs2881766 in isolation. The classic ESR1 functional polymorphisms rs2234693 (PvuII, intron 1) and rs9340799 (XbaI, intron 1) are the most studied variants in this gene and may interact with rs2881766 effects through haplotype structure. Women carrying risk alleles at both rs2881766 and rs9340799 may face compounded gestational hypertension risk, as rs9340799 GG has independently been associated with severe preeclampsia in multiple studies.

Your LDL cholesterol is cleared from the bloodstream primarily by a receptor protein called the LDL receptor (LDLR)¹¹ LDL receptor (LDLR)
A cell-surface protein on liver cells that binds LDL particles and pulls them out of circulation for degradation. Without enough functional LDLR, LDL accumulates in the blood from birth, silently depositing cholesterol in artery walls decades before symptoms appear. The LDLR Cys667Tyr variant is one of over 1,700 known pathogenic mutations in this gene that cause familial hypercholesterolemia (FH)²² familial hypercholesterolemia (FH)
An inherited disorder of LDL cholesterol metabolism; the most common serious Mendelian disease, affecting ~1 in 250 people in its heterozygous form.

The Mechanism

The rs28942083 A allele encodes a missense substitution at position 667 of the LDLR protein — cysteine to tyrosine (p.Cys667Tyr). Cysteine-667 is located in the EGF precursor homology domain³³ EGF precursor homology domain
A domain required for proper protein folding and recycling of the receptor after LDL delivery inside the cell of the receptor. This cysteine normally participates in a critical disulfide bond. When replaced by tyrosine, the bond cannot form, the protein misfolds, and it is retained in the endoplasmic reticulum⁴⁴ retained in the endoplasmic reticulum
The cellular compartment where newly synthesized proteins are folded and quality-checked before being dispatched to the cell surface instead of reaching the liver cell surface.

Functional studies in fibroblasts from a homozygous patient⁵⁵ Functional studies in fibroblasts from a homozygous patient
Leitersdorf et al., J Clin Invest 1990 showed that only 20% of LDLR protein was processed to its mature surface form; independent assays measured residual LDLR activity below 2%. This near-complete loss of function is the molecular basis of the disease phenotype.

The Evidence

FH caused by LDLR loss-of-function mutations is one of the best-characterized genetic disorders in medicine. A 2013 consensus statement from the European Atherosclerosis Society⁶⁶ A 2013 consensus statement from the European Atherosclerosis Society
Nordestgaard et al., Eur Heart J 2013 based on 63,000 individuals established that untreated heterozygous FH carriers face a 22-fold elevated risk of coronary artery disease compared to the general population, with untreated men reaching a 50% probability of a fatal or nonfatal coronary event by age 50 and untreated women by age 60.

Untreated LDL-C in heterozygous FH typically exceeds 190 mg/dL (4.9 mmol/L); homozygous individuals often reach 400–600 mg/dL. Without treatment, xanthomas (cholesterol deposits in tendons and skin) and premature cardiovascular disease are near-universal by the fourth or fifth decade of life.

The p.Cys667Tyr variant is particularly prevalent in French Canadian populations⁷⁷ French Canadian populations
Due to a founder effect tracing to a small founding population in Québec in the 17th century, where it is known as the "FH French Canadian-2" allele and accounts for a substantial fraction of FH cases in that community. The variant has also been identified across European populations in over 40 documented heterozygous individuals.

High-intensity statin therapy (e.g., rosuvastatin 20–40 mg or atorvastatin 40–80 mg) reduces LDL-C by approximately 50%, and registry studies show that treated FH patients have cardiovascular event rates roughly half those of untreated carriers. Many patients require additional agents — ezetimibe (further 20% LDL reduction) or PCSK9 inhibitors such as evolocumab or alirocumab (50–60% additional reduction) — to reach guideline targets.

Practical Actions

Carrying even one copy of this variant is a medical finding that warrants immediate attention from a lipid specialist or cardiologist. The primary intervention is aggressive pharmacological lowering of LDL-C, started as early as possible — ideally in childhood for heterozygous FH — to reduce lifetime arterial cholesterol exposure. Dietary changes that limit saturated fat intake (below 7% of total calories) reduce LDL-C by a further 8–15% and are a meaningful complement to drug therapy but cannot substitute for it.

Cascade screening of first-degree relatives (parents, siblings, children) is essential: heterozygous FH follows autosomal dominant inheritance, so each first-degree relative has a 50% probability of carrying the same variant.

Interactions

The rs28942083 A allele acts dominantly — one copy is sufficient to cause FH. Its severity in heterozygotes can be modulated by variants in other lipid genes:

• PCSK9 rs11591147 (R46L) — Loss-of-function PCSK9 variants partially offset LDLR deficiency by reducing PCSK9-mediated LDLR degradation, resulting in attenuated but not eliminated LDL elevation.
• APOE rs429358 / rs7412 (ε2 allele) — The APOE ε2 isoform reduces LDL-C clearance demand, and ε2 carriers with LDLR mutations sometimes show less severe phenotypes, though this is not consistent across studies.
• rs6511720 (LDLR regulatory intron 1) — This common regulatory variant modestly increases LDLR expression; carriers of both rs6511720 T and rs28942083 A may produce slightly more functional receptor from the non-mutant allele.

These interactions do not eliminate the need for pharmacological treatment but may explain phenotypic variability among heterozygous FH carriers. Compound heterozygosity with a second LDLR pathogenic variant (two different LDLR mutations, one on each chromosome) produces a phenotype approaching that of homozygous FH and requires aggressive management.